Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Live Updating

Newer

BrazenBull

02/14/16 5:45 PM

Post #11

Re: #10: @crudeoil24 - Tutes loading up again. Last summer PFNX had

putting this on my watch list.

crudeoil24

02/13/16 10:50 AM

Post #10

Tutes loading up again. Last summer PFNX had over 80% shares owned by tutes.

crudeoil24

02/13/16 10:24 AM

Post #9

Re: #8: @crudeoil24 - Company coming off its 52-wk. low yesterday.

PFNX, HSP/(PFE) ink collaboration for Lucentis FoB:

http://finance.yahoo.com/news/pfenex-hospira-announce-collaboration-develop-141500337.html
Quote:
Pfenex Inc. and Hospira, Inc…today announced that the companies have entered into an agreement to exclusively develop and commercialize for worldwide sales PF582, Pfenex's biosimilar candidate to Genentech's Lucentis (ranibizumab injection).

Under the terms of the collaboration, Pfenex will receive an upfront payment of $51 million once the collaboration receives antitrust approval, and, over the next five years and beyond, will be eligible to receive a combination of development and sales-based milestone payments up to an additional $291 million, and tiered double-digit royalty on net sales of the product.

Pfenex and Hospira will share the Phase 3 equivalence clinical trial costs, and Hospira will be responsible for manufacturing and commercializing the product worldwide.

crudeoil24

02/13/16 10:06 AM

Post #8

Re: #7: @crudeoil24 - Filing 8-K > Pfenex Inc. (the “Company”) and

Company coming off its 52-wk. low yesterday.

crudeoil24

02/13/16 10:05 AM

Post #7

Re: #6: @crudeoil24 - Several Form 4's, 13-G's & a 8-K out

Filing 8-K > Pfenex Inc. (the “Company”) and Wells Fargo Bank, National Association (“Wells Fargo”) had entered into that certain Amended and Restated Credit Agreement and the Amended and Restated Revolving Line of Credit Note by and between the Company and Wells Fargo dated July 1, 2015 (together, the “Amended Credit Facility”). On February 11, 2016, the parties agreed to terminate the Amended Credit Facility, and the Company repaid the approximately $3.8 million outstanding under the Amended Credit Facility using its restricted cash. The Company did not incur any termination penalties in connection with the termination of the Amended Credit Facility. The material terms of the Amended Credit Facility are described in the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on July 6, 2015 and are incorporated herein by reference.

crudeoil24

02/13/16 10:04 AM

Post #6

Re: #5: @crudeoil24 - Pfenex Inc. is a clinical-stage biotechnology company. The

Several Form 4's, 13-G's & a 8-K out this month.

crudeoil24

02/13/16 9:47 AM

Post #5

Re: #4: @BrazenBull - What is it these guys do? Could be

Pfenex Inc. is a clinical-stage biotechnology company. The Company is engaged in the development of biosimilar therapeutics and high-value and difficult to manufacture proteins. The Company's lead product candidate is PF582, a biosimilar candidate to Lucentis (ranibizumab). The Company is conducting a Phase Ib/IIa trial for PF582 in patients with wet age-related macular degeneration (wet AMD). The Company's next most advanced product candidate is PF530, a biosimilar candidate to Betaseron (interferon beta-1b). The Company's pipeline includes five other preclinical biosimilar products under development, such as PF726, PF529, PF688, PF694 and PF444. It is also developing a vaccine Px563L, which is an anthrax vaccine candidate; a generic product PF708, and next generation biologic candidates. The Company's product candidates are enabled by its patented protein production platform, Pfenex Expression Technology.

http://www.pfenex.com